Sökning: "newly-diagnosed"
Visar resultat 31 - 35 av 157 avhandlingar innehållade ordet newly-diagnosed.
31. Magnetic Resonance Imaging as a Screening Tool for Prostate Cancer
Sammanfattning : The overall aim of this thesis was to explore the role of Magnetic resonance imaging (MRI) of the prostate as an adjunct to the prostate-specific antigen (PSA)-test in screening for prostate cancer (PCa), focusing on the performance of MRI in detecting clinically significant PCa within the randomised controlled GÖTEBORG Prostate Cancer Screening 2 Trial. By inviting men 50–60 years of age to different screening strategies—PSA cut-off for biopsy 3. LÄS MER
32. Genetic and environmental factors in relation to childhood type 1 diabetes mellitus aetiology and clinical presentation in Sweden and Lithuania
Sammanfattning : Background. Incidence of Type I diabetes mellitus (DM) is increasing worldwide. It is affecting mostly young people, with the dramatically rising incidence among youngest children (those under age of 5 years). LÄS MER
33. Hope and Despair : Philosophy of life, expectations and optimism in cancer patients and their spouses
Sammanfattning : The general aim was to explore philosophy of life, expectations and optimism in patients and spouses in two different cancer situations, and to determine whether these aspects had relevance for psychological distress and quality of life. The first situation was being newly diagnosed with advanced cancer. LÄS MER
34. Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate
Sammanfattning : The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML). Imatinib mesylate (imatinib, Glivec® or Gleevec®), a small molecule inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for all newly diagnosed chronic phase CML patients. LÄS MER
35. Mantle cell lymphoma strategies in primary treatment
Sammanfattning : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. LÄS MER